Authored By: Sarah
11 Jul 2024

 Cancer Biologics Market Size to grow by USD 51.08 billion between 2024-2028

According to a research report “ Cancer Biologics Market” by Product (Monoclonal antibodies, Cell and gene therapy, Vaccines, Others) Route Of Administration (Injectable, Oral) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 51.08 billion, at a CAGR of  9.18% during the forecast period. Cancer, a chronic disease characterized by the abnormal and uncontrolled proliferation of cells, is a significant global health concern. The primary causes of cancer include genetic mutations, environmental factors such as tobacco use and pollution, and shifting dietary habits. These factors have led to an alarming increase in the global incidence of cancer, making it the second leading cause of death worldwide. In 2020, there were approximately 19.3 million new cancer cases and 10 million cancer-related deaths reported globally. Notably, in the US, cancers such as melanoma, prostate cancer, kidney cancer, liver cancer, lung cancer, breast cancer, uterine cancer, thyroid cancer, and bladder cancer accounted for a substantial number of new cases.

Browse market data tables, figures, and in-depth TOC on “Cancer Biologics Market” by Product (Monoclonal antibodies, Cell and gene therapy, Vaccines, Others) Route Of Administration (Injectable, Oral) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Product, the Monoclonal antibodies segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Route Of Administration, Injectable  segment is expected to hold the largest market size for the year 2024

Monoclonal antibodies represent a significant segment of targeted therapies and immunotherapies in the cancer treatment landscape. These therapeutic agents inhibit tumor growth by interacting with specific targets, namely angiogenic cascade proteins, thereby impeding cancer progression and carcinogenesis. Monoclonal antibodies exert their effects by modifying the behavior of cancer cells, including their division, repair, growth, and interactions with other cells. The therapeutic potential of monoclonal antibodies is substantial, given their ability to selectively target cancerous cells with minimal impact on healthy cells. Notable approved monoclonal antibodies in the market include Herceptin, Avastin, MabThera/Rituxan, XGEVA, Vectibix, BLINCYTO, OPDIVO, EMPLICITI, YERVOY, LARTRUVO, PORTRAZZA, ERBITUX, CYRAMZA, PERJETA, KADCYLA, TECENTRIQ, GAZYVA, and KEYTRUDA. The high demand for these life-saving treatments underscores the immense value they bring to patients battling various types of cancer.

North America is forecasted to hold the largest market size by region in 2024

The North American cancer biologics market is experiencing significant growth due to the increasing incidence of various types of cancer, including breast cancer, esophageal cancer, pancreatic cancer, gynecological cancers, and rare cancers such as neuroblastoma. According to the CDC, approximately 237,000 breast cancer cases are diagnosed annually in the US, while the NIH estimates that around 650 children are diagnosed with neuroblastoma each year. Regulatory authorities, such as the FDA, are accelerating market expansion by granting approvals for innovative cancer biologics. This trend is expected to continue, driving market growth in the region.

The Cancer Biologics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biocon Ltd.
  • Biogen Inc.
  • Bristol Myers Squibb Co.
  • Celltrion Co. Ltd.
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Jazz Pharmaceuticals Plc
  • Johnson and Johnson
  • Lupin Ltd.
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Cancer Biologics Market encompasses a range of therapies, including cell-based immunotherapies, gene therapy, cytokines, and monoclonal antibodies, administered through various routes such as Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) infusions. These biologic drugs are used to treat various types of cancers, including colorectal and stomach, in both humans and animal living organisms. Online pharmacies, retail pharmacies, and hospital pharmacies play a crucial role in the distribution of these drugs. IM and SC injections are commonly used for administering cytokines like Interleukins, while IV infusions are the preferred method for delivering cell-based therapies, gene therapy, and antibodies. Traditional chemotherapy continues to be a significant part of cancer treatment, but innovative treatments like biologic drugs are gaining popularity due to their ability to target specific molecular targets in cancer biology. However, the high cost of these treatments and complex reimbursement policies pose challenges for insurance providers and patients. Fatalities from cancer continue to be a major health concern, making the development of new and effective treatments a priority in cancer biotechnology. The market for cancer biologics is expected to grow significantly in the coming years as more innovative treatments are developed and approved for use.

Market Research Overview

The Cancer Biologics Market is experiencing significant growth due to patent expirations of blockbuster oncology drugs, leading to an increase in the availability and affordability of biologic therapies. This market includes a range of treatments such as cell-based immunotherapies, gene therapy, cytokines, and monoclonal antibodies. These therapies are administered through various routes including intramuscular, subcutaneous, and intravenous, and are used to treat various types of cancer such as colorectal, liver, lung, neck, breast, prostate, nasopharyngeal, and blood cancers like multiple myeloma, lymphoma, and leukemia. Biotechnology firms and advanced hospitals are at the forefront of oncology research, developing innovative treatments such as CAR-T cell therapies and immune checkpoint inhibitors. These therapies have shown promising results in treating minimal residual disease and improving treatment outcomes. However, they come with side effects such as rash, vomiting, nausea, diarrhea, weakness, injection site reactions, and allergic reactions. Regulatory authorities are playing a crucial role in the development and approval of these therapies. Key players in the market include Avastin, Tecentriq, Durvalumab, Blinatumomab, Cemiplimab-rwlc, Atezolizumab, and Pembrolizumab. The market is also influenced by the regulatory environment, healthcare expenditure, research & development capabilities, and reimbursement policies. Cancer centers and specialized healthcare professionals such as radiation oncologists, hematologists, medical oncologists, and nurses provide comprehensive care to cancer patients. Biologic drugs are administered through various routes including oral, infusion, and injection, and can be derived from human, animal, or living organisms. Biotechnology advancements and research organizations are playing a crucial role in the development of new cancer treatments and diagnostic techniques. The aging population and lifestyle changes are contributing to an increase in cancer incidence, further driving the growth of the cancer biologics market. The market is segmented into oncology biologics, blood cancer segment, and monoclonal antibodies segment. Traditional chemotherapy, radiation therapy, and surgery continue to be important treatment modalities, but biologic drugs are becoming increasingly popular due to their targeted action on molecular targets and minimal side effects. Insurance providers play a crucial role in the affordability and accessibility of these therapies. Cancer biology and innovative treatments continue to be areas of active research and development in the field of cancer biotechnology.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio